Ibogaine under scrutiny after Presley Gerber's death

Presley Gerber, son of Cindy Crawford and Rande Gerber, passed away at a Santa Monica rehabilitation facility, sparking renewed interest in ibogaine, a controversial treatment he mentioned in a March Instagram post. Although no connection between ibogaine and Gerber's death has been confirmed, the incident has brought attention to the drug's potential heart risks, according to Medical Daily.

What the investigation reveals

Santa Monica police are treating Gerber's death as a suspected overdose, while the Los Angeles County Medical Examiner has postponed determining the cause and manner of death pending further tests. Newsweek reports that the medical examiner's office noted such cases can take months to resolve, with no indications of foul play currently present.

Ibogaine's risks and legal status

Ibogaine, derived from the African shrub Tabernanthe iboga, is known for its psychoactive properties. While it is illegal in the United States as a Schedule I substance, it remains unregulated in Mexico, where many clinics offer treatment. CNN highlights that ibogaine can cause serious heart rhythm disturbances, potentially leading to cardiac arrest and sudden death. A 2022 review identified 58 ibogaine-related emergencies, including 38 fatalities, often involving underlying health issues or concurrent drug use.

Promising yet limited research

Research into ibogaine's therapeutic potential continues. A Stanford Medicine study published in Nature Medicine in January 2024 involved 30 veterans with traumatic brain injuries receiving ibogaine in a monitored Mexican clinic. Participants reported significant reductions in PTSD, depression, and anxiety symptoms after one month, with no severe side effects. However, the study's small size and lack of a control group limit its conclusions.

Regulatory and safety considerations

Federal and state interest in ibogaine research is growing. Former President Donald Trump signed an executive order to expedite psychedelic treatment development, including ibogaine, allocating $50 million in federal funds. Texas and Arizona have also invested in ibogaine research. Despite these efforts, ibogaine remains illegal outside approved research in the U.S., and its use poses significant heart risks, particularly for individuals with pre-existing heart conditions or recent opioid use.

Why it matters

Gerber's death underscores the complexities and risks associated with ibogaine treatment, highlighting the need for more comprehensive research and regulation. While early studies suggest potential benefits for addiction and PTSD, the drug's safety profile remains a concern. Families considering ibogaine should explore FDA-approved alternatives like buprenorphine, methadone, and naltrexone, and consult healthcare professionals before proceeding.

The Los Angeles County Medical Examiner's findings on Gerber's cause of death are pending, with further federal and state trials expected to provide more controlled safety data on ibogaine.